Elizabeth Gough-Gordon, Digital Content Editor

Changes to a patient’s microbiome that are characterized as healthy after fecal microbiota transplantation (FMT) may be sustained for up to 21 weeks post-transplant.

Patients with Clostridium difficile infection (CDI) are twice as likely to be readmitted to the hospital compared to patients without this infection.

Emergent BioSolutions announced that the Food and Drug Administration (FDA) has approved Anthrasil (anthrax immune globulin intravenous [human]), also known as AIGIV, for the treatment of inhalation anthrax in combination with appropriate antibacterial drugs.

The Food and Drug Administration (FDA) issued recommendations for healthcare professionals regarding endoscopic retrograde cholangiopancreatography (ERCP) endoscopes (duodenoscopes).